PTC Therapeutics (PTCT) Tops Q2 EPS by 6c

PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($1.14), $0.06 better than the analyst estimate of ($1.20). Revenue for the quarter came in at $6.77 million versus the consensus estimate of $7.74 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• William Blair Upgrades Backblaze Inc (BLZE) to Market Perform
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen